The single transmembrane domain serine/threonine kinase activin receptor type IIB (ActRIIB) has been proposed to bind key regulators of skeletal muscle mass development, including the ligands GDF-8 (myostatin) and GDF-11 (BMP-11). Here we provide a detailed kinetic characterization of ActRIIB binding to several low and high affinity ligands using a soluble activin receptor type IIB-Fc chimera (ActRIIB.Fc). We show that both GDF-8 and GDF-11 bind the extracellular domain of ActRIIB with affinities comparable with those of activin A, a known high affinity ActRIIB ligand, whereas BMP-2 and BMP-7 affinities for ActRIIB are at least 100-fold lower. Using site-directed mutagenesis, we demonstrate that ActRIIB binds GDF-11 and activin A in different ways such as, for example, substitutions in ActRIIB Leu(79) effectively abolish ActRIIB binding to activin A yet not to GDF-11. Native ActRIIB has four isoforms that differ in the length of the C-terminal portion of their extracellular domains. We demonstrate that the C terminus of the ActRIIB extracellular domain is crucial for maintaining biological activity of the ActRIIB.Fc receptor chimera. In addition, we show that glycosylation of ActRIIB is not required for binding to activin A or GDF-11. Together, our findings reveal binding specificity and activity determinants of the ActRIIB receptor that combine to effect specificity in the activation of distinct signaling pathways.

The biogenic synthesis of silver nanoparticles (AgNPs) are gaining attention because they are eco-friendly, non-hazardous, economical and devoid of the drawbacks of physicochemical processes. Biogenic approaches for synthesizing nanoparticles (NPs) using plant leaves, seeds, bark, stems, fruits, roots and flowers are highly cost-effective compared to other methods. Silver (Ag) has been used since ancient times, but biogenic AgNPs have only been made in the last few decades. They have been employed primarily in the food and pharmaceutical industries as antimicrobials and antioxidants. Recent studies have confirmed that many molecules present in different bacteria, including Escherichia coli, Staphylococcus aureus, Citrobacter koseri, Bacillus cereus, Salmonella typhi, Klebsipneumoniaoniae, Vibrio parahaemolyticus, Pseudomonas Aeruginosa, are bound to the AgNPs and can be inhibited using multifaceted mechanisms like AgNPs inter inside the cells, free radicals, ROS generation and modulate transduction pathways. Recent breakthroughs in nanobiotechnology-based therapeutics have opened up new possibilities for fighting microorganisms. Thus, in particular, biogenic AgNPs as powerful antibacterial agents have gained much interest. Surface charge, colloidal state, shape, concentration and size are the most critical physicochemical characteristics that determine the antibacterial potential of AgNPs. Based on this review, it can be stated that AgNPs could be made better in terms of their potency, durability, accuracy, biosecurity and compatibility.

Background: The incidence of fungal infections has increased significantly, contributing to morbidity and mortality. This is caused by an alarming increase in infections with multi-drug resistant bacteria leading to overuse of broad-spectrum antimicrobials, which lead to overgrowth of Candida, thus enhancing its opportunity to cause disease. Candida are major human fungal pathogens that cause both mucosal and deep tissue infections. Objective : The aim of our study was to identify the distribution of Candida species among clinical isolates and their sensitivity pattern for common antifungal drugs. Materials and Methods : Two hundred and thirty-seven different clinical isolates of Candida were collected from patients visiting to a tertiary care centre of Indore from 2010 to 2012. Identification of Candida species as well as antifungal sensitivity testing was performed with Vitek2 Compact (Biomerieux France) using vitek 2 cards for identification of yeast and yeast like organisms (ID-YST cards). Antifungal susceptibility testing was performed with Vitek2 "Fungal Susceptibility Card (AST YS01) kits respectively. Results : We found that the non-albicans Candida were more prevalent than Candida albicans in paediatric (60 year) patients than other age group (4-18, 19-60 years) patients and also in intensive care unit (ICU) patients as compared to out patient department (OPD) patients. Resistance rates for amphotericin B, fluconazole, flucytosine, itraconazole, and voriconazole were 2.9%, 5.9%, 0.0%, 4.2% and 2.5%%, respectively. All the strains of C. krusei were found resistant to fluconazole with intermediate sensitivity to flucytosine. Conclusion: Species-level identification of Candida and their antifungal sensitivity testing should be performed to achieve better clinical results.